Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1313P - Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) tumor expression in a phase I/II study of tusamitamab ravtansine (SAR408701) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

Date

16 Sep 2021

Session

ePoster Display

Topics

Pathology/Molecular Biology

Tumour Site

Presenters

Jean-Yves Scoazec

Citation

Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729

Authors

J. Scoazec1, A. Bauchet2, J. Adam3, P. Rochaix4, G. MacGrogan5, J.E. Kim6, P. Nuciforo7, F. López-Rios8, D. Frisman9, G. Cesarone9, S. Bernstein9, J. Lee9, C. Henry10, M. Ozoux11, A. Lefebvre11

Author affiliations

  • 1 N/a, Institut Gustave Roussy, 000 - Villejuif/FR
  • 2 N/a, Sanofi, 91380 - Chilly-Mazarin/FR
  • 3 N/a, Institut Gustave Roussy, Villejuif/FR
  • 4 N/a, Institut Claudius Regaud, Toulouse/FR
  • 5 N/a, Institut Bergonié, Bordeaux/FR
  • 6 N/a, Seoul National University College of Medicine Boramae Medical Center, Seoul/KR
  • 7 N/a, Vall d'Hebron Institute of Oncology, Barcelona/ES
  • 8 N/a, Hospital Universitario HM Sanchinarro, and CIBERONC, Madrid/ES
  • 9 N/a, Discovery Life Sciences, Goleta/US
  • 10 N/a, Sanofi, Vitry-sur-Seine/FR
  • 11 N/a, Sanofi, Chilly-Mazarin/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1313P

Background

CEACAM5 is a cell surface biomarker protein with high expression in NSCLC. Tusamitamab ravtansine (tusa; SAR408701) consists of an antibody-drug conjugate of a humanized CEACAM5-specific monoclonal antibody linked to DM4, a potent anti-tubulin agent. In a phase I/II study (NCT02187848), tusa showed antitumor activity in pretreated pts with advanced non-squamous NSCLC and high CEACAM5 expression. Here, we report CEACAM5 expression levels, patterns, and correlation with demographic variables in these pts.

Methods

CEACAM5 expression was assessed using available archival tumor samples and analyzed locally at clinical sites and/or centrally in a laboratory by immunohistochemistry using murine anti-CEACAM5 clone 769. High expression was defined as ≥ 50% of tumor cells per specimen with CEACAM5 positive staining at ≥ 2+ intensity; moderate expression was ≥ 1 to < 50% of tumor cells at ≥ 2+ intensity. CEACAM5 staining may exhibit a polarized (partial apical or basolateral) or whole (complete or partial) membrane pattern. CEACAM5 correlation with demographic variables was analyzed.

Results

Among 888 prescreened pts, 19.4% had high CEACAM5 expression and 23.6% had moderate expression. For high CEACAM5 expressors recruited in the study (N = 64), CEACAM5 staining was observed over the whole membrane (mean percentage of CEACAM5 positive cells at ≥ 2+ intensity = 51.95%) or was polarized (25.08%). Among CEACAM5 moderate expressors recruited (N = 28), mean percentage of CEACAM5 positive cells was 6.96% for whole membrane staining and 6.89% for polarized staining. No correlations were noted between CEACAM5 expression and pt sex, age, race, or ethnicity for either CEACAM5 high or moderate expressors.

Conclusions

Almost 20% of prescreened NSCLC pts had high CEACAM5 expression. High CEACAM5 expressors exhibited a mixed pattern of whole membrane and polarized staining, with a predominance of whole membrane expression. In CEACAM5 moderate expressors, whole membrane CEACAM5 expression was similar to polarized CEACAM5 expression. CEACAM5 expression was not correlated with demographic variables.

Clinical trial identification

NCT02187848.

Editorial acknowledgement

Editorial support was provided by Amanda Sheldon, PhD of inScience Communications (Philadelphia, PA, USA), funded by Sanofi.

Legal entity responsible for the study

Sanofi.

Funding

Sanofi.

Disclosure

A. Bauchet: Financial Interests, Personal, Full or part-time Employment: Sanofi. J. Adam: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Research Grant: MSD. P. Nuciforo: Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Research Grant: Bayer. F. López-Rios: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Thermo Fisher; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Role: Bayer; Financial Interests, Institutional, Research Grant: Lilly; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: Thermo Fisher; Financial Interests, Institutional, Research Grant: Pfizer. C. Henry: Financial Interests, Personal, Full or part-time Employment: Sanofi. M. Ozoux: Financial Interests, Personal, Full or part-time Employment: Sanofi; Financial Interests, Personal, Stocks/Shares: Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.